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Abstract In this study, we describe the incidence, treat-
ment, and outcome of breast cancer (BC) during the period
1994–2003 in the South-American country of Surinam and
compare these with those of BC in the Netherlands.
Pathology reports and hospital charts from all BC cases
diagnosed between 1994 and 2004 were retrieved from
Surinam’s single pathology laboratory and its five hospi-
tals. Data on demographics, tumor characteristics, treat-
ment, and follow-up were gathered. We compared our data
to BC statistics of first generation immigrants from Suri-
nam to the Netherlands. 421 patients were diagnosed with
BC during the study period. The age-adjusted incidence
rate was 26 per 100,000 compared to 65/100,000 in first
generation Surinamese women in the Netherlands. The
majority had a fairly advanced stage at presentation, with
60% of tumors larger than 2 cm, and 41.6% with lymph
node involvement. Because of the absence of radiotherapy
facilities, local treatment in most patients was radical
mastectomy. Adjuvant hormonal therapy (51.6%) was
administered more frequently than adjuvant chemotherapy
(20.3%). A significant number of patients were lost to
follow-up, resulting in a median follow-up duration of only
23 months. The 5-year overall survival was 79%. BC
incidence in Surinam is low compared to that in the wes-
tern world, but the advanced stage at diagnosis, the low
utilization of systemic adjuvant therapy, and the inadequate
follow-up may lead to poor outcomes. A number of steps
are underway to improve the level of cancer care in
Surinam.
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Introduction
Breast Cancer (BC) is the most common malignancy
experienced by women worldwide. However, the incidence
is the highest in developed countries, and relatively low in
the developing world [1].
The republic of Surinam is a former Dutch colony sit-
uated in South America, which gained independence in
1975. Its history of colonization, of slave labor and contract
laborers, has led to great ethnic diversity in its population
of almost 500,000 [2]. The major ethnic groups are of
Indian descent (the so-called Hindustani 27.4%), or mixed
African descent (the so-called Creoles 17.7%), Marroons
(descendants of runaway slaves, 14.7%), and Javanese
(descendants of Indonesian contract laborers, 14.6%) [3].
In the 1970s and 1980s, after independence and during a
period of civil unrest, mass emigration to the Netherlands
took place, so that the Netherlands now has a population of
almost 350,000 originally from Surinam [4].
In the year 2002, the Gross Domestic Product (GDP) per
capita was US $4, 447. The annual per capita health
expenditure was US $385, corresponding to an expenditure
of 8.6% of the GDP [5]. The equivalent numbers for the
USA in 2002 were US $36, 056 for GDP, and US $5,274 or
14.6% of the GDP for health [6].
There are five hospitals in Surinam, four of which are
in the capital of Paramaribo. Medical specialists have all
been trained, at least partly, in first world hospitals,
mostly in the Netherlands. Surinam has one pathology
laboratory in Paramaribo, where all biopsies and surgical
specimens obtained anywhere in the country are sent.
Radiotherapy was not available in Surinam during the
study period, and so the patients who were eligible for
radiotherapy had to go out of the country to receive it. A
substantial part of the population has limited health care
coverage, and many patients have to contribute to the cost
of health care out of private funds. There is at present no
cancer registry.
Because of the paucity of data on BC in Surinam, the
aim of this study was to retrospectively investigate the
epidemiology, treatment, and outcome of BC over the last
decade to establish the baseline situation for future health
care planning and evaluation. We compared these data to
BC statistics of first generation immigrants from Surinam
to the Netherlands.
Methods
Between June 1, 2005 and September 30, 2005, data were
collected for all the patients having had a pathological
diagnosis of invasive BC between January 1, 1994 and
December 31, 2003.
After retrieval from the pathology laboratory archives,
the patient charts in the different hospitals were collected
and hand-searched for the following data: patient demo-
graphics; tumor characteristics (including TNM-stage,
grade, and hormone receptor status); treatment character-
istics, and follow-up data. The last date of follow-up was
the last recorded hospital contact, or death of patient.
During the study period, there were no national guidelines
for treatment of breast cancer.
This study was approved by the Ministry of Health, the
National Medical Ethics Board, the boards of directors and
the medical staffs of all the hospitals in Surinam. The
medical ethics committee of Surinam granted a waiver for
informed consent for this archival study. Data on Suri-
namese women with breast cancer in the Netherlands were
retrieved from the Netherlands Cancer Registry. We used
data for the provinces of North-Holland and Flevoland,
which host 35% of the Surinamese population in the
Netherlands.
Analysis
A database was made in Access to store all data. The
interval between the different therapies was calculated in
this program. Kaplan–Meyer curves and survival times
were calculated in SPSS. The age standardized incidence
rate was calculated using the World Standard population.
Results
Incidence
From January 1, 1994 until December 31, 2003, 421
patients were diagnosed with BC in Suriname, two were
male. The median incidence was 38.5/year with a peak of
70 patients in the year 2000. The crude incidence rate in the
study period was 15.7/100,000/year. The age-adjusted
incidence rate was 28/100,000/year (Table 1). The age-
adjusted incidence rate for first generation Surinamese
women in the Netherlands over the same period of time
was 65/100,000/year (Table 1).
Patient characteristics
The median age at BC diagnosis was 55 years, with a range
of 26–90. BC incidence is higher in Surinamese women in
the Netherlands than in Surinamese women in Surinam,
and this seems to be especially true for women aged more
than 55 (Fig. 1). BC occurs more often in Creoles (35.7/
100,000/year), than in Hindustani (18.2/100,000/year), and
Javanese women (20.8/100,000/year) (Table 2).
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Data on parity (n = 173) and age at first pregnancy
(n = 61) were not available for the majority of patients.
Data on lactation and duration of lactation were so scarce
that they were left out of this report.
Tumor characteristics
In Surinam, ductal cancers were most common (94%), with
a minority of lobular tumors (1.7%) and tumors of
unknown origin (4.3%) (Table 3).
More than 60% of all tumors were T2 ([20 and
\50 mm) and larger, while less than a quarter were T1
(\20 mm). In almost 15% of cases, tumor size was not
known, either because the patients never came back after
the diagnostic biopsy for further treatment, or because they
were not eligible for surgery due to tumor spread at
presentation.
The lymph node status was known for 323 patients, with
almost equal numbers with tumor-positive (N?) and
tumor-negative (N0) axillary nodes. The 96 patients with
an unknown axillary node status were either patients who
only had a diagnostic biopsy and did not return for further
treatment or had an advanced stage at presentation, and
hence were not eligible for surgery.
The hormone receptor status was known for 69 patients
only (Table 3), 40% of whom had a positive estrogen
receptor (ER) and/or progesterone receptor (PgR). All but
two of these hormone receptor tests were done after 2000.
At the time of presentation, a small number of patients
(5.7%) had distant metastases. The majority of tumors for
which the histological grade was known, was poorly dif-
ferentiated according to the Bloom–Richardson classifica-
tion. The mitotic activity index (MAI), which was
determined in Surinam from the year 2000, was known for
Table 1 Characteristics of
breast cancer patients in
Surinam and Surinamese
women in the provinces North-
Holland and Flevoland in the
Netherlands, 1994–2003
*ASR age-standardized rate per
100,000 women/year
Surinam The Netherlands
Number of
patients (ASR*)
% Number of
patients (ASR*)
%
Total 419 (28) 196 (65)
1994–1998 167 (25) 88 (62)
1999–2003 252 (31) 108 (68)
Age
\30 3 0.7 2 1.0
30–39 43 10.3 29 14.8
40–49 108 25.8 42 21.4
50–59 94 22.4 53 27.0
60–69 94 22.4 44 22.4
[70 75 17.9 26 13.3
Unknown 2 0.5 –
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95 tumors, of which 53.7% had a MAI B10 mitotic figures/
10 hpf, and 46.3% had a MAI [10 mitotic figures/10 hpf.
Treatment
A large majority (79.7%) of patients underwent surgery.
Modified radical mastectomy was the procedure most often
performed, with some form of breast conserving therapy
for a minority of patients (Table 4). The 20.3% of patients
who did not receive surgery were diagnosed with BC, but
they either never came back for further treatment or had
had an advanced stage of BC and were thus not eligible for
surgery.
Hormone therapy was prescribed for 216 (51.6%)
patients. The lymph node status was known for 186 of
these patients, and 62% of N? patients and 52% of N0
patients received hormone therapy.
In the 78 N0 patients who received hormone therapy, the
indications for hormone therapy were T1 tumor with BR 3
(n = 4), T3 or T4 tumor (n = 9), T2 with a BR2 or 3
(n = 27). For 38 patients, the indication for hormone
therapy was not specified. 18 of 26 patients, who had
positive hormone receptors, received hormone therapy.
The eight patients with a positive hormone receptor, who
did not receive hormone therapy, either had died or were
lost to follow-up soon after diagnosis.
One fifth of all the patients received adjuvant chemo-
therapy. This was not appreciably influenced by the size of
the primary tumor. Chemotherapy was given to 35.1% of
all node positive (N?) patients. Fifty-one percent of N?
women \50 years, and 20% of N? women [50 years
received chemotherapy. 17% of N0 women\50 years, and
4% of N0 women [50 years received chemotherapy.
Among all patients, 30% of whom were eligible for
chemotherapy according to the 2005 Surinam guidelines
(obviously not available during the study period) actually
received it in our cohort.
Also, 33 patients (of 42 who had breast conserving
surgery) were irradiated abroad after lumpectomy. 26
patients received radiotherapy after radical mastectomy.
The indication for adjuvant radiotherapy was irradical
Table 2 Characteristics of breast cancer patients in Surinam
1994–2003
Strata Number of
patients
% Incidence rate/
100,000/year
Ethnicity
Creole 156 37.2 35.7
Marroons 8 1.9 2.2
Hindustani 123 29.4 18.2
Javanese 75 17.9 20.8
Chinese 8 1.9
Mixed 31 7.4 10.1
Dutch 6 1.4
Others 12 2.9
Parity
0 15 3.6
1–3 92 22.0
[3 66 15.8
Unknown 246 58.7
Age of first pregnancy
\20 22 5.3
20–30 34 8.1
30–40 5 1.2
Unknown 358 85.4
Table 3 Tumor characteristics of breast cancer patients in Surinam
Strata Number of patients %
Total 419 100
Type of tumor
Ductal 394 94
Lobular 7 1.7
Unknown 18 4.3
T-size
T1 (B20 mm) 98 23.4
T2 ([20, B50 mm) 157 37.5
[T3 ([50 mm) 96 22.9
Unknown 68 16.2
Number of involved axillary lymph nodes
N0 149 35.6
N1(1–3) 93 22.2
N2(4–9) 51 12.2
N3(C10) 30 7.2
Unknown 96 23.2
Metastases 24 5.7
ER/PgR
ER?/PgR? 26 6.2
ER-/PgR- 39 9.3
ER?/PgR- 2 0.5
ER-/PgR? 2 0.5
Unknown 350 83.5
Bloom-Richardson differentiation
Well = grade 1 7 1.7
Moderately = grade 2 52 12.4
Poor = grade 3 181 43.2
Unknown 179 42.7
Mitotic activity index
B10 51 12.2
[10 44 10.5
Unknown 324 77.3
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resection in five patients, T3 tumor (n = 3), T4 tumor
(n = 3), age \35 years (n = 2), ER-/PgR- (n = 2), and
grossly positive lymph nodes ([N2 in 7 patients). For four
patients who were treated with adjuvant radiotherapy after
mastectomy, the indication could not be retrieved from the
available records.
Treatment duration
The median time from the date of diagnosis until the date
of surgery in Surinam was 17 days, with not much vari-
ation between the different hospitals in Paramaribo. The
median time between breast conserving surgery in Suri-
nam and radiotherapy abroad was 11 weeks. For the 26
patients who received radiotherapy after mastectomy, the
median time between mastectomy and radiotherapy was
11.5 weeks.
The median time between surgery and second treatment
modality, either chemotherapy or radiotherapy was
9 weeks. The median time from the end of the first to the
start of the second adjuvant treatment modality was
12 weeks.
Outcome
Follow-up data of 384 (91.7%) patients were available, but
median follow-up was only 23 months. 5-year follow-up
was available for 73 patients. The 5-year overall survival
for these patients was 79%, with a median of 110 months
(Fig. 2).
During follow-up, 45 patients were diagnosed with
distant metastases, 47 with a locoregional relapse, and 27
with both distant spread and locoregional relapse. Patients
who received breast conserving therapy developed loco-
regional relapse in 9.1% of cases, while in patients who
underwent mastectomy the locoregional relapse rate was
20.5%.
The mean disease-free survival was 100 months (Fig. 2),
and highly correlated to T stage, with 111 months for T1
tumors, 94 months for T2 tumors, 77 months for T3 tumors,
and for T4 tumors 44 months. For patients with negative
lymph node status, mean survival was 116 months, and for
positive lymph node status, it was 78 months (Fig. 3).
Discussion
In this retrospective population-based survey, the incidence
of BC in Surinam was studied over a 10-year period. The
Table 4 Therapy
characteristics of breast cancer
patients in Surinam
n % Lymph node
positive
Lymph node
negative
Total 419 100
Surgery 334 79.7
Mastectomy 292 69.7 150 127
Lumpectomy 42 10.0 14 20
Radiotherapy 59 13.8 33 24
after lumpectomy 33 7.9 20 16
after mastectomy 26 5.9 13 8
Chemotherapy 86 20.5
CMF 45 10.5 35 4
Anthracycline-containing 31 7.9 21 7
Unknown 10 1.9
Hormone therapy (Tamoxifen) 216 51.6 107 76
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Fig. 2 Overall and disease-free survival of breast cancer patients in
Surinam
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strength of this study lies in the fact that all pathology-
confirmed diagnoses in the country were included in the
analysis, and all hospitals participated. The main weakness
is the paucity of follow-up data with a median follow-up of
less than 2 years, which impedes discussion of outcome.
Although all pathologically confirmed BC diagnoses in
Surinam during the study period were included in the
analyses, it is conceivable that additional women were
diagnosed with advanced BC during the study period
without tumor biopsies or surgery. The absence of a
national cancer registry in the country makes it impossible
to estimate or correct for this in any way. However, this is
the first population-based study to look at individual
demographic, tumor, and treatment data.
The crude cancer incidence rate in Surinam increased
from 9.5/100,000 during 1964–1976 [7] to 16.7/100,000
during 1980–2000 [8], which is similar to our results. The
rise in BC incidence over the past decades is seen world-
wide [9, 10] and has been mostly correlated with changes
in reproductive factors. This may to a large degree account
for the lower BC incidence in developing countries versus
the western world [11, 12]. Although increasing, the mean
age at first birth in Surinam is still low at 21 years [5],
compared to over 28 years in most western European
countries [13]. In addition, mean parity in Surinam was 2.7
children per women in 2000 [3], while in the Netherlands,
it was only 1.7 (2001–2003) [13]. Interestingly, the inci-
dence of BC in Surinamese women in Surinam was con-
siderably lower than the incidence of first generation
Surinamese women in the Netherlands (Fig. 1). The main
possible explanation is thought to lie in demographic
changes, with Surinamese women in the Netherlands
adapting to Dutch reproductive statistics with less children
at a higher age, although increased detection due to public
awareness and screening mammography programs may
also play a part.
The median age at BC diagnosis was lower than the
median age in the western world, albeit being fairly high
compared to other low-income countries, underlining the
in-between state of development of Surinam society [11,
12, 14]. A confounding factor could be the relatively low
life expectancy of women in Surinam (69 years at birth [5],
versus 80 in the USA [6]), especially in view of the fact
that 43% of new BC cases in the USA are diagnosed in
women older than 65 years. The most important competing
risk for death in Surinam is cardiovascular disease, which
has a high mortality because (preventive) care is not always
optimized.
The fact that the proportion of Creole BC patients is
higher than that would be expected by the distribution of
ethnicities in the population may both be explained by not
only genetic factors comparable to the incidence data for
e.g., African-Americans in the USA, but also by much
higher prevalence of cardiovascular disease in Hindustanis,
the largest ethnic group.
Women presented with late stage BC more often than in
the western world, e.g., 41.6% of patients had lymph node
involvement at time of diagnosis, whereas during the same
time period, this was only 30% in the USA and 31% in the
Netherlands [15]. More advanced stage at diagnosis is
commonly found in developing countries [14], and is
thought to be related to lack of universal coverage, lack of
screening programs, and fear of cancer in general. Tumor
size and stage decreased in the western world since the
introduction of mammography in the Netherlands in the
last decades of the twentieth century [16–18], and this went
hand in hand with increased public awareness and reduced
taboo status of the disease [19, 20]. In Surinam, the vivid
culture of traditional medicine and taboo status of BC,
almost certainly, contribute to a more advanced stage at
diagnosis. However, the convergence of both incidence and
stage of BC in first generation immigrants from Surinam to
the native Dutch population challenges the size of the
effect of different attitude and beliefs. It underscores both
the relationship between poor socioeconomic status and
access to health care, and the positive effect of BC cam-
paigns to enhance BC awareness and possibly of screening
[21].
Although data on tumor size and lymph node status were
generally available from the pathology lab, other prog-
nostic and predictive factors were harder to interpret. We
found a discrepancy between the Mitotic Activity Index
(MAI) and Bloom–Richardson grading. The majority of
tumors had low MAI (under 10 hpf), but this was paired
with high tumor grades according to Bloom–Richardson
Grading which is generally considered more subjective and
0 20 40 60 80 100 120 140
Survival in months
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Fig. 3 Overall cumulative survival of breast cancer patients with N0/
N? in Surinam
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less reproducible than MAI. According to several authors,
MAI is a strong, widely available, easily assessable, inex-
pensive, well-reproducible prognosticator, if the protocol is
carefully followed. Fixation delay for as long as 24 h after
extirpation of the tumor does not decrease the accuracy of
the MAI, in contrast to BR evaluation [22]. In a country
with limited resources, MAI could prove to be more reli-
able than grading, but short of central pathology revision,
there is no way of knowing what was the most accurate or
consistent in Surinam.
Because of the absence of immunohistochemistry (IHC)
technology in the pathology laboratory in Surinam to
determine hormone receptor status, paraffin-embedded
archival tissues were sent to the Netherlands to determine
the receptor status of the tumor whenever deemed necessary
for treatment decisions. Unfortunately, only a minority of
patients had tissue sent to the Netherlands, and most of them
had a negative receptor status. Is this an accurate estimation?
False negatives of hormone receptor are not uncommon,
especially with increasing time delay before tissue fixation,
increased duration of fixation, and type of fixative, all of
which may have been the case in our patient cohort. False
negatives increase especially in BC with a low receptor
positivity such as is typically seen in patients of African
descent [23–26]. At present, it is impossible to say whether
this played a part in our study population, but the lack of IHC
to determine predictive markers is bound to hamper treat-
ment decision making, and possibly outcome. Thus, since
hormone receptor status was known for only 69 patients,
prescription of adjuvant hormone therapy was mostly blin-
ded to ER-status. This seems not unreasonable, in view of
the uncertainty about the quality of the assessments, and the
mild cost and systemic effects of hormone therapy.
The indications for adjuvant systemic therapy for BC
have broadened over the past decades. Although regional
differences exist, in general adjuvant systemic therapy is
prescribed for larger tumors, N? tumors, and small tumors
that are poorly differentiated. No guideline existed in
Surinam during the study period, but in 2005, the National
Oncology Committee developed a BC treatment guideline
based on both Dutch and American (USA) guidelines [27,
28], although, in some cases, the suggested drug regimens
differed to suit Surinam’s economical situation [5]. Indi-
cations for adjuvant systemic therapy according to this
government-approved guideline were compared to the
proportion of patients receiving such therapy in the study
cohort. It should be noted that over the study time period,
in western countries, adjuvant chemotherapy practice was
also considerably more conservative than it is now. The
aim of the comparison was mainly to assist in future health
care planning.
A minority of patients who would be eligible for adju-
vant chemotherapy according to the guideline actually
received it (30%). Based on western experience after the
introduction of national guidelines [29], this number could
go up to at least 70% for chemotherapy, which means that
the number of patients that will receive adjuvant chemo-
therapy may double or even triple.
The treatment interval between the different treatment
modalities is a predictor for outcome, with a long treatment
interval as an unfavorable factor. Compared to the Neth-
erlands, the median interval between diagnosis and surgery
was shorter (17 days vs. around 28 days), which points to
the absence of long waiting lists for surgery so common in
the Netherlands. However, treatment intervals between
surgery and chemotherapy compared unfavorably to the
Netherlands (9 vs. 4 weeks). We speculate that the lack of
availability of cytotoxic drugs in Surinam may in some
case account for the delay, but the lack of a sense of
urgency in both doctors and patients may also play a part.
The time between surgery and radiotherapy was
approximately 11 weeks. In the Netherlands, an 8-week
interval is considered as the upper limit of what is
acceptable, with a preference for 4–6 weeks. Because of
the absence of radiotherapy facilities within the country, a
longer interval may have been unavoidable in this group. In
view of this, it may be worth considering advising radical
mastectomy instead of breast conserving therapy for all
patients, until radiotherapy will become available in the
country.
For a relatively large part of our cohort (20–25%), no
data on lymph node status or local treatment were avail-
able. Some of these patients may not have received local
treatment because of advanced stage of disease at time of
diagnosis, but we speculate that others never returned for
further treatment. This is consistent with the relatively
short length of follow-up, in spite of our concerted efforts
to track down the disease course of all patients. We were
unable to determine whether patients in general did not
return for follow-up because disease was uncontrolled, or
because they were asymptomatic. In either case, this may
have biased the survival data, which raises doubt about
their validity, even though obvious trends such as worse
outcome for higher stages could be confirmed.
Conclusion
In this study, we have shown the feasibility of conducting a
nationwide epidemiologic survey in Surinam. Most of our
findings could be related to the demographics of Surinam
and the low-resource status of the economy. The intro-
duction of the Surinam BC treatment guideline, the plan-
ned introduction of immunohistochemistry, and the
anticipated introduction of radiotherapy in late 2010 are
expected to ameliorate diagnosis and treatment of BC
Breast Cancer Res Treat (2011) 128:873–881 879
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patients in Surinam. The projected start of a national cancer
registry, combined with a recently improved continued
medical education program will further enhance these
goals. Improvement in BC awareness and possible imple-
mentation of BC screening programs will take much
longer.
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